S100A10 and neoplasm: Based on these considerations, we demonstrated that vascular co-option mechanism could be reliably recognized, using immunohistochemical techniques, as metabolically overactive (evaluated as mitochondria expression) P-gp+ or S100A10+ tumor cells surrounding CD31+ ECs with reduced P-gp and mitochondria expression.